Maria Verdugo

Fundación Chile — Chile

Medicine · Health Sciences

21h-index4.6kcitations46works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(30), Lymphoma Diagnosis and Treatment(19), Multiple Myeloma Research and Treatments(11), Acute Lymphoblastic Leukemia research(11), Protein Degradation and Inhibitors(10)

Publications45 total

Is the self-report of number of teeth in adults valid in compared to the traditional oral examination? (Epistemonikos).
2024Open Access
Local Anaesthetics Combined with Vasoconstrictors in Controlled Hypertensive Patients Undergoing Dental Procedures: Systematic Review and Meta-Analysis
International journal of odontostomatology·2023Open Access
The Work-Load Index – a Succinct Tool to Gauge Patient Acuity and Ensure Appropriate Staffing
Transplantation and Cellular Therapy·2021
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Blood·2019· 169 citedOpen Access
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy
Haematologica·2019· 40 citedOpen Access
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
Blood·2019· 69 citedOpen Access
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Journal of Clinical Oncology·2018· 294 citedOpen Access
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor
British Journal of Haematology·2018· 15 citedOpen Access
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
Annals of Oncology·2018· 72 citedOpen Access
Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.
Journal of Clinical Oncology·2018· 1 cited
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Journal of Clinical Oncology·2018· 305 citedOpen Access
Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies
Future Oncology·2018· 62 citedOpen Access
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Blood·2018· 131 citedOpen Access
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
The Lancet Oncology·2017· 372 citedOpen Access
Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)
Blood·2017· 5 cited
Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma
Blood·2017· 15 cited
Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy
Blood·2017· 18 cited
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Blood·2017· 517 citedOpen Access
Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial
Clinical Lymphoma Myeloma & Leukemia·2017· 6 cited
Modified Venetoclax Dose Ramp-Up in Select High-Risk Patients with Chronic Lymphocytic Leukemia (CLL) with Progression after B-Cell Receptor Pathway Inhibitors (BCRi)
Clinical Lymphoma Myeloma & Leukemia·2017· 5 cited
page 1 of 3Next →

Frequent Co-authors

Matthew S. Davids(19), William G. Wierda(18), Andrew W. Roberts(17), John F. Seymour(14), Jeremy A. Ross(14), Lang Zhou(12), Jalaja Potluri(12), Brenda Chyla(11), Rod Humerickhouse(11), Michael Y. Choi(11), Steven Coutré(10), Paulo Maciag(10), Ming Zhu(9), Richard R. Furman(9), Ahmed Hamed Salem(8), Su Young Kim(8), Shaji Kumar(8), Thierry Façon(8), Philippe Moreau(8), Joel Johansson(8)